Incannex Healthcare Inc
IXHL0.365USD
-0.011-3.05%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
71.01MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Incannex Healthcare Inc Unternehmen
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Incannex Healthcare Inc Informationen
BörsenkürzelIXHL
Name des UnternehmensIncannex Healthcare Inc
IPO-datumMar 18, 2022
CEOMr. Joel Latham
Anzahl der mitarbeiter9
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse8 Century Circuit
Stadt
BörseNASDAQ Capital Market Consolidated
LandAustralia
Postleitzahl2153
Telefon61409840786
Website
BörsenkürzelIXHL
IPO-datumMar 18, 2022
CEOMr. Joel Latham
Führungskräfte von Incannex Healthcare Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
+26.96%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
+3.36%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
+10.17%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
--
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
+26.96%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
+3.36%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
+10.17%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
--
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2022
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Australia
74.00K
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Latham (Joel)
0.45%
Valentine (Troy Robert)
0.30%
Anastassov (George)
0.22%
Changoer (Lekhram)
0.18%
AdvisorShares Investments, LLC
0.14%
Andere
98.71%
Aktionäre
Aktionäre
Anteil
Latham (Joel)
0.45%
Valentine (Troy Robert)
0.30%
Anastassov (George)
0.22%
Changoer (Lekhram)
0.18%
AdvisorShares Investments, LLC
0.14%
Andere
98.71%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
1.28%
Corporation
1.11%
Investment Advisor
0.27%
Investment Advisor/Hedge Fund
0.03%
Research Firm
0.02%
Andere
97.28%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
38
3.08M
0.89%
+1.73M
2025Q2
39
10.29M
34.95%
+3.27M
2025Q1
36
6.86M
34.69%
+1.54M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Latham (Joel)
1.24M
0.36%
-335.00K
-21.24%
Apr 09, 2025
Valentine (Troy Robert)
869.01K
0.25%
-167.50K
-16.16%
Apr 09, 2025
Anastassov (George)
744.72K
0.21%
-25.00K
-3.25%
Apr 09, 2025
Changoer (Lekhram)
639.55K
0.18%
--
--
Apr 09, 2025
AdvisorShares Investments, LLC
343.95K
0.1%
+48.92K
+16.58%
Jun 30, 2025
LPL Financial LLC
323.90K
0.09%
+323.90K
--
Jun 30, 2025
Widdows (Peter)
245.85K
0.07%
-25.00K
-9.23%
Apr 09, 2025
Geode Capital Management, L.L.C.
116.35K
0.03%
--
--
Aug 31, 2025
Commonwealth Financial Network
55.27K
0.02%
+55.27K
--
Jun 30, 2025
Clark (Robert)
75.00K
0.02%
-25.00K
-25.00%
Apr 09, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
AdvisorShares Psychedelics ETF
1.59%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
Anteil1.59%
Amplify Alternative Harvest ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
